LeapRate's Daily Forex Industry Newsletter
Join now to receive first access to our EXCLUSIVE reports and updates.
Screenshot of a breaking news alert e-mail from Q2 2017
Eris Exchange, a U.S.-based futures exchange group that offers swap futures as a capital-efficient alternative to traditional over-the-counter (OTC) interest rate swaps, today announced that it has received a patent on the principal component of its product design, the Eris Methodology, by the U.S. Patent and Trademark Office. The patented invention enables a cash-settled futures product to replicate the convexity of an OTC swap by incorporating interest on collateral within daily variation margin payments.
Eris utilizes the invention in its flagship U.S. dollar-denominated Eris Swap Futures contracts that clear at CME. Open interest in these contracts has grown by 65% in the past 18 months. In addition, Eris has licensed the Eris Methodology for use in products on multiple global futures exchanges, including ICE Futures U.S. and ICE Futures Europe. Open interest in all products based on the Eris Methodology now exceeds 200,000 contracts, representing more than 70% of global swap futures open interest.
Eris’ recent growth has been fueled by fixed income investors and hedgers using Eris Swap Futures as a more cost-effective and operationally-efficient way to conduct their business,” said Neal Brady, CEO of Eris Exchange. “Receiving a U.S. patent further validates the uniqueness and superior product design of the Eris Methodology, and ensures that Eris is well-positioned to reap the benefits of the value we’re providing to clients.
The Eris Methodology means that Eris Swap Futures may be held until the final maturity of the underlying swap, with no forced rolls or physical delivery, therefore replicating both the risk and mechanics of the equivalent OTC swap,” said Tom Rettinger, Managing Director, Portfolio Risk Management at PennyMac. Consequently, Eris Swap Futures may be used in the same manner as OTC swaps, while enjoying the protections and benefits of an exchange traded instrument.
John Coleman, Managing Director of R.J. O’Brien Fixed Income Group added:
Last year we illustrated how Eris contracts may be suitable as designated hedges under GAAP (see RJO-FIG issues Eris Hedge Accounting Paper). Proposed FASB updates to ASC 815 on Derivatives and Hedging should make the use of Eris Swap Futures even easier and cheaper to implement.
The Eris invention, which in 2015 received patent protection in Japan, is titled “Non-biased, centrally-cleared financial instrument and method of clearing and settling,” (U.S. Patent No. 9,747,641).